Corporate News Report: Pavmed Inc. (PAVM)
- Closing Price: USD 2.20
- Daily Change: –2.15 %
- Volume: USD 30.5 k (approximately 13,864 shares traded)
- Supply: 1.5 million shares outstanding
- Market Capitalisation: USD 16.8 million
- Year‑to‑Date Performance (since last month‑end): –48.6 %
- 200‑Day Simple Moving Average: USD 6.75
- 52‑Week High: USD 28.44 (recorded 01/21/2026)
- 52‑Week Low: USD 2.04 (recorded 10/22/2026)
Recent Corporate Actions
| Item | Details |
|---|
| Private Placement | On 21 Oct 2026, subsidiary Lucid Diagnostics sold 15,000 shares of Series C Convertible Preferred Stock to long‑term shareholders. The company will file a resale registration statement covering the underlying common shares within 120 days. |
| Medicare Reimbursements | Lucid Diagnostics began receiving Medicare payments for its EsoGuard® esophageal DNA test at the established fee‑schedule rate. The claim activity is intended to support commercial expansion and strengthen the balance sheet. |
| Strategic Impact | The financing and reimbursement initiatives are expected to provide resources for near‑term operations and working capital. They may also influence the shareholder structure through the conversion terms of the preferred shares. |
| Stock | % Change | Current Price | Market Cap |
|---|
| Neuphoria Therapeutics (NEUP) | +2.65 % | USD 3.38 | USD 18.8 M |
| Array (3664.TW) | 0 % | TWD 8.36 | TWD 645.5 M |
| Aware /Mass (AWRE) | –3.33 % | USD 0.88 | USD 19.6 M |
| Marker Therapeutics (MRKR) | –5.31 % | USD 0.99 | USD 18.8 M |
| Modular Medical (MODD) | +1.03 % | USD 1.80 | USD 18.7 M |
Company Profile
Pavmed Inc. is a U.S.‑based medical device company operating within the health‑care equipment & supplies sector. Its product portfolio includes disposable infusion pumps, short‑term catheters, percutaneous and tissue ablation devices, and long‑term vascular access devices. The company continues to expand its market presence through product innovation and strategic partnerships.
